American pharmaceutical company Moderna confirmed that their COVID-19 vaccine is effective and safe to use for children under the age of 6.
Nearly 7,000 children aged six months to six years were given two doses of Moderna’s mRNA-based COVID-19 vaccination or two doses of placebo in the research conducted by Moderna, where none of the infected children in the research developed serious illness, were hospitalized, or died.
Children who received the shot developed antibodies against SARS-CoV-2 at similar levels as adults who received higher doses of the vaccine, which indicated that children’s immune systems are more active and efficient.
Moderna elaborated in a statement that the findings were part of the company’s KidCOVE trial and that the data will be submitted to the Food and Drug Administration (FDA) for emergency use authorization in the youngest group of children eligible for COVID-19 vaccination.
Moderna’s vaccine is currently only approved for people over the age of 18, but Pfizer-vaccine BioNTech’s is approved for adults and has emergency use authorization for children aged five to 18.
“Given the need for a vaccine against COVID-19 in infants and young children we are working with the U.S. FDA and regulators globally to submit these data as soon as possible.” said Stéphane Bancel, Chief Executive Officer of Moderna, and added that the company “Remain committed to helping to end the COVID-19 pandemic with a vaccine for children of all ages.”
Children under the age of six are the last age group to be vaccinated against COVID-19 in the United States.
© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.